So most of the mabs don't fit anymore.

大多数 mab 不再管用了。

To go broad. Scientists used to pick these mabs based on how strongly they attached to a particular virus.

扩大范围。以前，科学家们依据 mab 对特定病毒的附着强度来挑选药物。

These mabs were configured to fit that early virus, like a key fitting into a lock.

这些 mab 是为早期病毒量身打造的，就像为一把锁配的钥匙。

They've usually got long, difficult names, but they typically end in " mab, " so that's the giveaway.

这些新药的名字一般都很长很难懂，但通常都以“mab（单克隆抗体）”结尾，因此这透露了药品配方。

Not yet. There are about 10 of these mabs in various stages of testing.

还不行。现在有 10 余种 mab 正处于不同阶段测试中。

Mab developers are picking antibodies that take aim at what scientists call " highly conserved" regions of the virus.

Mab 研发者正在挑选能针对病毒“高度保守”区域的抗体。

Mab manufacturers can charge just over $2000 per dose.

Mab 生产商能开出每剂 2000 美元以上的高价。

Another advantage mabs have is they can be used to prevent infection in people who are in high-risk situations.

Mab 的另一优势是可用于预防高风险人群被感染。

In plain English that means spots that don't mutate from variant to variant, so the mabs can still lock on.

说白了就是那块区域不会随变异株而变异，继而 mab 能一直锁定病毒。

Look, I don't want to keep tossing out problems, but mabs aren't a pill like Paxlovid.

不是我想不停提问，但 mab 不是 Paxlovid 那种药片。

Some may be immunocompromised and don't get much benefit from vaccines, so mabs can play a prevention role for them.

其中一些人可能有免疫缺陷，他们打疫苗得不到多少益处，因此 mab 便可以保护他们。

It turns out, though, that mabs are actually cheap to produce these days, just one or two hundred bucks a pop.

但事实上，mab 现在的生产成本很低——每剂只有一两百美元。

I saw a study in which scientists tested 21 different " mabs" against the BA. 4 and 5 variants, and only one was able to neutralize them.

我看过一项研究，说科学家们测试了 21 种 mab 对抗 BA.4 和 BA.5 变异的情况，只有一种能中和病毒。